Safety/ Feasibility of Percutaneous Administration of Vonapanitase as Monotherapy for Peripheral Artery Disease (PAD) of the SFA and Popliteal Arteries

NCT02953496 | Withdrawn Phase 1 DMC

• 1 other identifier: PRT-201-110
• Study Type: interventional
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

The research study is designed to assess the technical feasibility and safety of percutaneous administration of vonapanitase to the superficial femoral or popliteal artery in patients with PAD.

Conditions

Peripheral Artery Disease

Keywords

peripheral artery disease; PAD; vonapanitase; claudication; superficial femoral artery; SFA; popliteal artery; stenosis; elastase; chymotrypsin-like elastase 1; CELA1; PRT-201

Outcome Measures

Primary Outcomes (2)

• Incidence of adverse events

  Safety assessments include physical exams, duplex Doppler ultrasound and routine serum chemistry and hematology tests

  Up to 6 months following study drug administration

• Technical success of percutaneous injection

  Technical success of study drug administration will be assessed by the extent of circumferential and longitudinal coverage of the artery using a protocol-defined assessment scale

  Intraprocedural

Other Outcomes (5)

• Peak systolic velocity ratio [PSVR]

  14 days and 6 months following study drug administration

• Minimum lumen diameter [MLD]

  14 days and 6 months following study drug administration

• Rutherford category

  14 and 28 days, and 6 months following study drug administration

Study Arms (1)

vonapanitase

EXPERIMENTAL

Drug: vonapanitase

Interventions

vonapanitase DRUG

Vonapanitase will be administered to the target lesion of the SFA or PA via percutaneous needle injection under ultrasound guidance.

Also known as: PRT-201

vonapanitase

Eligibility Criteria

• Age: 18 Years - 100 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age of at least 18 years.
• Clinical diagnosis of PAD secondary to atherosclerosis affecting a lower limb.
• ABI \<0.90 at rest or with exercise, or a toe-brachial index (TBI) \<0.70 if ABI value is \>1.30 (non-compressible), or radiographic evidence of PAD that correlates with clinical symptoms.
• Rutherford category 2-4.
• Screening duplex Doppler ultrasound with a SFA or PA lesion with a PSVR \>2.4.
• De novo lesion, not previously treated by angioplasty, atherectomy, or stent.
• If female and of childbearing potential (premenopausal and not surgically sterile) must have a negative pregnancy test at the screening visit and be willing to use contraception from the time of the screening visit to 1 week following study drug administration. Acceptable methods of birth control include abstinence, barrier methods with spermicide, implants, injectables, oral contraceptives, intra-uterine device, or a vasectomized partner.
• Ability to understand and comply with the requirements of the entire study and communicate with the study team.
• Ability to provide written informed consent using a document that has been approved by the required institutional review board.

You may not qualify if:

• Patients in whom arterial insufficiency in the lower extremity is the result of an immunologic or inflammatory non-atherosclerotic disorder (e.g., Buerger's disease, vasculitis).
• Total occlusion of the SFA or PA in the index leg.
• Planned surgical or endovascular procedures to the affected leg on the day of or within 28 days of study drug administration.
• Deep vein thrombosis within the past 3 months.
• Known bleeding disorder.
• Presence of any arterial aneurysm in the index leg.
• Known hypercoagulable state (e.g., protein C deficiency, factor V Leiden mutation, prothrombin G20210A mutation).
• Platelet count \<130K, hematocrit \<30%, bilirubin or ALT \>3.0 times the upper limit of normal.
• Arterial systolic BP \>200 mmHg or diastolic BP \>100 mmHg at screening or day of procedure.
• Pregnancy, lactation or plans to become pregnant during the course of the study.
• Presence of any significant medical condition that might significantly confound the collection of safety and efficacy data in this study.
• Malignancy or treatment for malignancy within the previous 12 months with the exception localized basal cell or squamous cell skin cancer, or any cancer in situ.
• Treatment with any investigational drug within the previous 30 days or investigational antibody therapy within 90 days prior to signing informed consent.
• Known allergy to contrast media, iodine, lidocaine, prilocaine, or EMLA Cream (lidocaine 2.5% and prilocaine 2.5%).

Sponsors & Collaborators

• Proteon Therapeutics: lead

Study Sites (1)

University of Virginia Health System

Charlottesville, Virginia, 22908, United States

Location

MeSH Terms

Conditions

Peripheral Arterial Disease; Intermittent Claudication; Constriction, Pathologic

Interventions

cholesterol-binding protein

Condition Hierarchy (Ancestors)

Atherosclerosis; Arteriosclerosis; Arterial Occlusive Diseases; Vascular Diseases; Cardiovascular Diseases; Peripheral Vascular Diseases; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Pathological Conditions, Anatomical

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 26, 2016
• First Posted: November 2, 2016
• Primary Completion: April 30, 2019
• Study Completion: April 30, 2019
• Last Updated: May 2, 2019

Record last verified: 2019-04

Locations

US (1)